miR	B:C1537896
-375	I:C1537896
inhibits	O
cancer	O
stem	I:C1956422
cell	I:C1956422
phenotype	O
and	O
tamoxifen	O
resistance	O
by	O
degrading	O
HOXB3	O
in	O
human	O
ER	O
-	I:C3640067
positive	I:C3640067
breast	O
cancer	I:C0678222
.	O

miR	O
-375	I:C1537896
inhibits	O
cancer	B:C1956422
stem	I:C1956422
cell	I:C1956422
phenotype	O
and	O
tamoxifen	O
resistance	O
by	O
degrading	O
HOXB3	O
in	O
human	O
ER	O
-	I:C3640067
positive	I:C3640067
breast	O
cancer	I:C0678222
.	O

miR	O
-375	I:C1537896
inhibits	O
cancer	O
stem	I:C1956422
cell	I:C1956422
phenotype	O
and	O
tamoxifen	B:C0039286
resistance	O
by	O
degrading	O
HOXB3	O
in	O
human	O
ER	O
-	I:C3640067
positive	I:C3640067
breast	O
cancer	I:C0678222
.	O

miR	O
-375	I:C1537896
inhibits	O
cancer	O
stem	I:C1956422
cell	I:C1956422
phenotype	O
and	O
tamoxifen	O
resistance	B:C0013203
by	O
degrading	O
HOXB3	O
in	O
human	O
ER	O
-	I:C3640067
positive	I:C3640067
breast	O
cancer	I:C0678222
.	O

miR	O
-375	I:C1537896
inhibits	O
cancer	O
stem	I:C1956422
cell	I:C1956422
phenotype	O
and	O
tamoxifen	O
resistance	O
by	O
degrading	O
HOXB3	B:C1415666
in	O
human	O
ER	O
-	I:C3640067
positive	I:C3640067
breast	O
cancer	I:C0678222
.	O

miR	O
-375	I:C1537896
inhibits	O
cancer	O
stem	I:C1956422
cell	I:C1956422
phenotype	O
and	O
tamoxifen	O
resistance	O
by	O
degrading	O
HOXB3	O
in	O
human	B:C0086418
ER	O
-	I:C3640067
positive	I:C3640067
breast	O
cancer	I:C0678222
.	O

miR	O
-375	I:C1537896
inhibits	O
cancer	O
stem	I:C1956422
cell	I:C1956422
phenotype	O
and	O
tamoxifen	O
resistance	O
by	O
degrading	O
HOXB3	O
in	O
human	O
ER	B:C3640067
-	I:C3640067
positive	I:C3640067
breast	O
cancer	I:C0678222
.	O

miR	O
-375	I:C1537896
inhibits	O
cancer	O
stem	I:C1956422
cell	I:C1956422
phenotype	O
and	O
tamoxifen	O
resistance	O
by	O
degrading	O
HOXB3	O
in	O
human	O
ER	O
-	I:C3640067
positive	I:C3640067
breast	B:C0678222
cancer	I:C0678222
.	O

Cancer	B:C1956422
stem	I:C1956422
cell	I:C1956422
(	O
Cancer	O
stem	I:C1956422
cell	I:C1956422
)	O
formation	O
and	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
(	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
)	O
are	O
pivotal	O
events	O
in	O
tumor	O
cell	I:C1269955
invasion	I:C1269955
and	O
metastasis	O
.	O

Cancer	O
stem	I:C1956422
cell	I:C1956422
(	O
Cancer	B:C1956422
stem	I:C1956422
cell	I:C1956422
)	O
formation	O
and	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
(	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
)	O
are	O
pivotal	O
events	O
in	O
tumor	O
cell	I:C1269955
invasion	I:C1269955
and	O
metastasis	O
.	O

Cancer	O
stem	I:C1956422
cell	I:C1956422
(	O
Cancer	O
stem	I:C1956422
cell	I:C1956422
)	O
formation	O
and	O
epithelial	B:C1523298
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
(	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
)	O
are	O
pivotal	O
events	O
in	O
tumor	O
cell	I:C1269955
invasion	I:C1269955
and	O
metastasis	O
.	O

Cancer	O
stem	I:C1956422
cell	I:C1956422
(	O
Cancer	O
stem	I:C1956422
cell	I:C1956422
)	O
formation	O
and	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
(	O
epithelial	B:C1523298
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
)	O
are	O
pivotal	O
events	O
in	O
tumor	O
cell	I:C1269955
invasion	I:C1269955
and	O
metastasis	O
.	O

Cancer	O
stem	I:C1956422
cell	I:C1956422
(	O
Cancer	O
stem	I:C1956422
cell	I:C1956422
)	O
formation	O
and	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
(	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
)	O
are	O
pivotal	O
events	O
in	O
tumor	B:C1269955
cell	I:C1269955
invasion	I:C1269955
and	O
metastasis	O
.	O

Cancer	O
stem	I:C1956422
cell	I:C1956422
(	O
Cancer	O
stem	I:C1956422
cell	I:C1956422
)	O
formation	O
and	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
(	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
)	O
are	O
pivotal	O
events	O
in	O
tumor	O
cell	I:C1269955
invasion	I:C1269955
and	O
metastasis	B:C4255448
.	O

They	O
have	O
been	O
shown	O
to	O
occur	O
in	O
resistance	B:C0013203
to	O
tamoxifen	O
.	O

They	O
have	O
been	O
shown	O
to	O
occur	O
in	O
resistance	O
to	O
tamoxifen	B:C0039286
.	O

Moreover	O
,	O
microRNAs	B:C1101610
(	O
microRNAs	O
)	O
have	O
been	O
associated	O
with	O
CSCs	O
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
as	O
well	O
as	O
tamoxifen	O
resistance	O
.	O

Moreover	O
,	O
microRNAs	O
(	O
microRNAs	B:C1101610
)	O
have	O
been	O
associated	O
with	O
CSCs	O
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
as	O
well	O
as	O
tamoxifen	O
resistance	O
.	O

Moreover	O
,	O
microRNAs	O
(	O
microRNAs	O
)	O
have	O
been	O
associated	O
with	O
CSCs	B:C1956422
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
as	O
well	O
as	O
tamoxifen	O
resistance	O
.	O

Moreover	O
,	O
microRNAs	O
(	O
microRNAs	O
)	O
have	O
been	O
associated	O
with	O
CSCs	O
,	O
epithelial	B:C1523298
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
as	O
well	O
as	O
tamoxifen	O
resistance	O
.	O

Moreover	O
,	O
microRNAs	O
(	O
microRNAs	O
)	O
have	O
been	O
associated	O
with	O
CSCs	O
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
as	O
well	O
as	O
tamoxifen	B:C0039286
resistance	O
.	O

Moreover	O
,	O
microRNAs	O
(	O
microRNAs	O
)	O
have	O
been	O
associated	O
with	O
CSCs	O
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
as	O
well	O
as	O
tamoxifen	O
resistance	B:C0013203
.	O

Studying	B:C2603343
molecular	O
mechanism	I:C3537153
of	O
CSCs	O
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
as	O
well	O
as	O
tamoxifen	O
resistance	O
will	O
help	O
us	O
to	O
further	O
understand	O
the	O
pathogenesis	O
and	O
progression	O
of	I:C0242656
the	I:C0242656
disease	I:C0242656
and	O
offer	O
new	O
targets	O
for	O
effective	O
therapies	O
.	O

Studying	O
molecular	B:C3537153
mechanism	I:C3537153
of	O
CSCs	O
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
as	O
well	O
as	O
tamoxifen	O
resistance	O
will	O
help	O
us	O
to	O
further	O
understand	O
the	O
pathogenesis	O
and	O
progression	O
of	I:C0242656
the	I:C0242656
disease	I:C0242656
and	O
offer	O
new	O
targets	O
for	O
effective	O
therapies	O
.	O

Studying	O
molecular	O
mechanism	I:C3537153
of	O
CSCs	B:C1956422
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
as	O
well	O
as	O
tamoxifen	O
resistance	O
will	O
help	O
us	O
to	O
further	O
understand	O
the	O
pathogenesis	O
and	O
progression	O
of	I:C0242656
the	I:C0242656
disease	I:C0242656
and	O
offer	O
new	O
targets	O
for	O
effective	O
therapies	O
.	O

Studying	O
molecular	O
mechanism	I:C3537153
of	O
CSCs	O
,	O
epithelial	B:C1523298
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
as	O
well	O
as	O
tamoxifen	O
resistance	O
will	O
help	O
us	O
to	O
further	O
understand	O
the	O
pathogenesis	O
and	O
progression	O
of	I:C0242656
the	I:C0242656
disease	I:C0242656
and	O
offer	O
new	O
targets	O
for	O
effective	O
therapies	O
.	O

Studying	O
molecular	O
mechanism	I:C3537153
of	O
CSCs	O
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
as	O
well	O
as	O
tamoxifen	B:C0039286
resistance	O
will	O
help	O
us	O
to	O
further	O
understand	O
the	O
pathogenesis	O
and	O
progression	O
of	I:C0242656
the	I:C0242656
disease	I:C0242656
and	O
offer	O
new	O
targets	O
for	O
effective	O
therapies	O
.	O

Studying	O
molecular	O
mechanism	I:C3537153
of	O
CSCs	O
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
as	O
well	O
as	O
tamoxifen	O
resistance	B:C0013203
will	O
help	O
us	O
to	O
further	O
understand	O
the	O
pathogenesis	O
and	O
progression	O
of	I:C0242656
the	I:C0242656
disease	I:C0242656
and	O
offer	O
new	O
targets	O
for	O
effective	O
therapies	O
.	O

Studying	O
molecular	O
mechanism	I:C3537153
of	O
CSCs	O
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
as	O
well	O
as	O
tamoxifen	O
resistance	O
will	O
help	O
us	O
to	O
further	O
understand	O
the	O
pathogenesis	B:C0699748
and	O
progression	O
of	I:C0242656
the	I:C0242656
disease	I:C0242656
and	O
offer	O
new	O
targets	O
for	O
effective	O
therapies	O
.	O

Studying	O
molecular	O
mechanism	I:C3537153
of	O
CSCs	O
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
as	O
well	O
as	O
tamoxifen	O
resistance	O
will	O
help	O
us	O
to	O
further	O
understand	O
the	O
pathogenesis	O
and	O
progression	B:C0242656
of	I:C0242656
the	I:C0242656
disease	I:C0242656
and	O
offer	O
new	O
targets	O
for	O
effective	O
therapies	O
.	O

Studying	O
molecular	O
mechanism	I:C3537153
of	O
CSCs	O
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
as	O
well	O
as	O
tamoxifen	O
resistance	O
will	O
help	O
us	O
to	O
further	O
understand	O
the	O
pathogenesis	O
and	O
progression	O
of	I:C0242656
the	I:C0242656
disease	I:C0242656
and	O
offer	O
new	O
targets	O
for	O
effective	O
therapies	B:C0087111
.	O

In	O
the	O
present	O
study	B:C2603343
,	O
we	O
showed	O
that	O
miR	O
-375	I:C1537896
inhibits	O
CSC	O
traits	I:C1956422
in	O
breast	O
cancer	I:C0678222
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
.	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
miR	B:C1537896
-375	I:C1537896
inhibits	O
CSC	O
traits	I:C1956422
in	O
breast	O
cancer	I:C0678222
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
.	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
miR	O
-375	I:C1537896
inhibits	O
CSC	B:C1956422
traits	I:C1956422
in	O
breast	O
cancer	I:C0678222
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
.	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
miR	O
-375	I:C1537896
inhibits	O
CSC	O
traits	I:C1956422
in	O
breast	B:C0678222
cancer	I:C0678222
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
.	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
miR	O
-375	I:C1537896
inhibits	O
CSC	O
traits	I:C1956422
in	O
breast	O
cancer	I:C0678222
MCF	B:C0596890
-	I:C0596890
7	I:C0596890
cells	I:C0596890
.	O

Bioinformatics	B:C1140694
analysis	O
and	O
experimental	O
validation	I:C1519941
identified	O
HOXB3	O
as	O
a	O
direct	O
target	O
of	O
miR-375	O
.	O

Bioinformatics	O
analysis	B:C0936012
and	O
experimental	O
validation	I:C1519941
identified	O
HOXB3	O
as	O
a	O
direct	O
target	O
of	O
miR-375	O
.	O

Bioinformatics	O
analysis	O
and	O
experimental	B:C1519941
validation	I:C1519941
identified	O
HOXB3	O
as	O
a	O
direct	O
target	O
of	O
miR-375	O
.	O

Bioinformatics	O
analysis	O
and	O
experimental	O
validation	I:C1519941
identified	O
HOXB3	B:C1415666
as	O
a	O
direct	O
target	O
of	O
miR-375	O
.	O

Bioinformatics	O
analysis	O
and	O
experimental	O
validation	I:C1519941
identified	O
HOXB3	O
as	O
a	O
direct	O
target	O
of	O
miR-375	B:C1537896
.	O

Overexpressing	B:C0017262
miR-375	O
degraded	O
HOXB3	O
mRNA	O
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
.	O

Overexpressing	O
miR-375	B:C1537896
degraded	O
HOXB3	O
mRNA	O
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
.	O

Overexpressing	O
miR-375	O
degraded	O
HOXB3	B:C1415666
mRNA	O
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
.	O

Overexpressing	O
miR-375	O
degraded	O
HOXB3	O
mRNA	B:C0035696
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
.	O

Overexpressing	O
miR-375	O
degraded	O
HOXB3	O
mRNA	O
in	O
MCF	B:C0596890
-	I:C0596890
7	I:C0596890
cells	I:C0596890
.	O

Moreover	O
,	O
overexpression	B:C0017262
of	O
HOXB3	O
induced	O
formation	O
of	O
CSC	O
phenotypes	I:C1956422
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
and	O
tamoxifen	O
-	O
resistance	O
as	O
well	O
as	O
enhanced	O
ability	O
of	O
migration	O
and	O
invasion	O
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
.	O

Moreover	O
,	O
overexpression	O
of	O
HOXB3	B:C1415666
induced	O
formation	O
of	O
CSC	O
phenotypes	I:C1956422
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
and	O
tamoxifen	O
-	O
resistance	O
as	O
well	O
as	O
enhanced	O
ability	O
of	O
migration	O
and	O
invasion	O
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
.	O

Moreover	O
,	O
overexpression	O
of	O
HOXB3	O
induced	O
formation	O
of	O
CSC	B:C1956422
phenotypes	I:C1956422
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
and	O
tamoxifen	O
-	O
resistance	O
as	O
well	O
as	O
enhanced	O
ability	O
of	O
migration	O
and	O
invasion	O
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
.	O

Moreover	O
,	O
overexpression	O
of	O
HOXB3	O
induced	O
formation	O
of	O
CSC	O
phenotypes	I:C1956422
,	O
epithelial	B:C1523298
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
and	O
tamoxifen	O
-	O
resistance	O
as	O
well	O
as	O
enhanced	O
ability	O
of	O
migration	O
and	O
invasion	O
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
.	O

Moreover	O
,	O
overexpression	O
of	O
HOXB3	O
induced	O
formation	O
of	O
CSC	O
phenotypes	I:C1956422
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
and	O
tamoxifen	B:C0039286
-	O
resistance	O
as	O
well	O
as	O
enhanced	O
ability	O
of	O
migration	O
and	O
invasion	O
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
.	O

Moreover	O
,	O
overexpression	O
of	O
HOXB3	O
induced	O
formation	O
of	O
CSC	O
phenotypes	I:C1956422
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
and	O
tamoxifen	O
-	O
resistance	B:C0013203
as	O
well	O
as	O
enhanced	O
ability	O
of	O
migration	O
and	O
invasion	O
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
.	O

Moreover	O
,	O
overexpression	O
of	O
HOXB3	O
induced	O
formation	O
of	O
CSC	O
phenotypes	I:C1956422
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
and	O
tamoxifen	O
-	O
resistance	O
as	O
well	O
as	O
enhanced	O
ability	O
of	O
migration	B:C1533574
and	O
invasion	O
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
.	O

Moreover	O
,	O
overexpression	O
of	O
HOXB3	O
induced	O
formation	O
of	O
CSC	O
phenotypes	I:C1956422
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
and	O
tamoxifen	O
-	O
resistance	O
as	O
well	O
as	O
enhanced	O
ability	O
of	O
migration	O
and	O
invasion	B:C2699153
in	O
MCF	O
-	I:C0596890
7	I:C0596890
cells	I:C0596890
.	O

Moreover	O
,	O
overexpression	O
of	O
HOXB3	O
induced	O
formation	O
of	O
CSC	O
phenotypes	I:C1956422
,	O
epithelial	O
-	I:C1523298
mesenchymal	I:C1523298
transition	I:C1523298
and	O
tamoxifen	O
-	O
resistance	O
as	O
well	O
as	O
enhanced	O
ability	O
of	O
migration	O
and	O
invasion	O
in	O
MCF	B:C0596890
-	I:C0596890
7	I:C0596890
cells	I:C0596890
.	O

Most	O
ER	B:C3640067
-	I:C3640067
positive	I:C3640067
breast	O
cancer	I:C0678222
-	O
related	O
deaths	O
occur	O
,	O
because	O
of	O
resistance	O
to	O
standard	O
therapies	O
and	O
metastasis	O
,	O
restoring	O
miR-375	O
or	O
targeting	O
HOXB3	O
might	O
serve	O
as	O
potential	O
therapeutic	O
approaches	O
for	O
the	O
treatment	O
of	O
tamoxifen	O
-	I:C0678222
resistant	I:C0678222
breast	I:C0678222
cancer	I:C0678222
.	O

Most	O
ER	O
-	I:C3640067
positive	I:C3640067
breast	B:C0678222
cancer	I:C0678222
-	O
related	O
deaths	O
occur	O
,	O
because	O
of	O
resistance	O
to	O
standard	O
therapies	O
and	O
metastasis	O
,	O
restoring	O
miR-375	O
or	O
targeting	O
HOXB3	O
might	O
serve	O
as	O
potential	O
therapeutic	O
approaches	O
for	O
the	O
treatment	O
of	O
tamoxifen	O
-	I:C0678222
resistant	I:C0678222
breast	I:C0678222
cancer	I:C0678222
.	O

Most	O
ER	O
-	I:C3640067
positive	I:C3640067
breast	O
cancer	I:C0678222
-	O
related	O
deaths	B:C0011065
occur	O
,	O
because	O
of	O
resistance	O
to	O
standard	O
therapies	O
and	O
metastasis	O
,	O
restoring	O
miR-375	O
or	O
targeting	O
HOXB3	O
might	O
serve	O
as	O
potential	O
therapeutic	O
approaches	O
for	O
the	O
treatment	O
of	O
tamoxifen	O
-	I:C0678222
resistant	I:C0678222
breast	I:C0678222
cancer	I:C0678222
.	O

Most	O
ER	O
-	I:C3640067
positive	I:C3640067
breast	O
cancer	I:C0678222
-	O
related	O
deaths	O
occur	O
,	O
because	O
of	O
resistance	O
to	O
standard	O
therapies	B:C0087111
and	O
metastasis	O
,	O
restoring	O
miR-375	O
or	O
targeting	O
HOXB3	O
might	O
serve	O
as	O
potential	O
therapeutic	O
approaches	O
for	O
the	O
treatment	O
of	O
tamoxifen	O
-	I:C0678222
resistant	I:C0678222
breast	I:C0678222
cancer	I:C0678222
.	O

Most	O
ER	O
-	I:C3640067
positive	I:C3640067
breast	O
cancer	I:C0678222
-	O
related	O
deaths	O
occur	O
,	O
because	O
of	O
resistance	O
to	O
standard	O
therapies	O
and	O
metastasis	B:C4255448
,	O
restoring	O
miR-375	O
or	O
targeting	O
HOXB3	O
might	O
serve	O
as	O
potential	O
therapeutic	O
approaches	O
for	O
the	O
treatment	O
of	O
tamoxifen	O
-	I:C0678222
resistant	I:C0678222
breast	I:C0678222
cancer	I:C0678222
.	O

Most	O
ER	O
-	I:C3640067
positive	I:C3640067
breast	O
cancer	I:C0678222
-	O
related	O
deaths	O
occur	O
,	O
because	O
of	O
resistance	O
to	O
standard	O
therapies	O
and	O
metastasis	O
,	O
restoring	O
miR-375	B:C1537896
or	O
targeting	O
HOXB3	O
might	O
serve	O
as	O
potential	O
therapeutic	O
approaches	O
for	O
the	O
treatment	O
of	O
tamoxifen	O
-	I:C0678222
resistant	I:C0678222
breast	I:C0678222
cancer	I:C0678222
.	O

Most	O
ER	O
-	I:C3640067
positive	I:C3640067
breast	O
cancer	I:C0678222
-	O
related	O
deaths	O
occur	O
,	O
because	O
of	O
resistance	O
to	O
standard	O
therapies	O
and	O
metastasis	O
,	O
restoring	O
miR-375	O
or	O
targeting	O
HOXB3	B:C1415666
might	O
serve	O
as	O
potential	O
therapeutic	O
approaches	O
for	O
the	O
treatment	O
of	O
tamoxifen	O
-	I:C0678222
resistant	I:C0678222
breast	I:C0678222
cancer	I:C0678222
.	O

Most	O
ER	O
-	I:C3640067
positive	I:C3640067
breast	O
cancer	I:C0678222
-	O
related	O
deaths	O
occur	O
,	O
because	O
of	O
resistance	O
to	O
standard	O
therapies	O
and	O
metastasis	O
,	O
restoring	O
miR-375	O
or	O
targeting	O
HOXB3	O
might	O
serve	O
as	O
potential	O
therapeutic	O
approaches	O
for	O
the	O
treatment	B:C0087111
of	O
tamoxifen	O
-	I:C0678222
resistant	I:C0678222
breast	I:C0678222
cancer	I:C0678222
.	O

Most	O
ER	O
-	I:C3640067
positive	I:C3640067
breast	O
cancer	I:C0678222
-	O
related	O
deaths	O
occur	O
,	O
because	O
of	O
resistance	O
to	O
standard	O
therapies	O
and	O
metastasis	O
,	O
restoring	O
miR-375	O
or	O
targeting	O
HOXB3	O
might	O
serve	O
as	O
potential	O
therapeutic	O
approaches	O
for	O
the	O
treatment	O
of	O
tamoxifen	B:C0678222
-	I:C0678222
resistant	I:C0678222
breast	I:C0678222
cancer	I:C0678222
.	O

